A citation-based method for searching scientific literature

H J Lambers Heerspink, D de Zeeuw, L Wie, B Leslie, J List. Diabetes Obes Metab 2013
Times Cited: 472



Tuba M Ansary, Daisuke Nakano, Akira Nishiyama. Int J Mol Sci 2019
Times Cited: 71




List of shared articles



Times cited

Cardiorenal protection with SGLT2 inhibitors in patients with diabetes mellitus: from biomarkers to clinical outcomes in heart failure and diabetic kidney disease.
Hongyan Liu, Vikas S Sridhar, Jacinthe Boulet, Atit Dharia, Abid Khan, Patrick R Lawler, David Z I Cherney. Metabolism 2022
3


Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Water and Sodium Metabolism.
Jun Tang, Lifang Ye, Qiqi Yan, Xin Zhang, Lihong Wang. Front Pharmacol 2022
0


Sodium-Glucose Cotransporter-2 Inhibitors Improve Heart Failure with Reduced Ejection Fraction Outcomes by Reducing Edema and Congestion.
Michelle Hernandez, Ryan D Sullivan, Mariana E McCune, Guy L Reed, Inna P Gladysheva. Diagnostics (Basel) 2022
1

SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na+ transport in Dahl SS rats.
Olha Kravtsova, Ruslan Bohovyk, Vladislav Levchenko, Oleg Palygin, Christine A Klemens, Timo Rieg, Alexander Staruschenko. Am J Physiol Renal Physiol 2022
0

SGLT2 inhibitors, sodium and off-target effects: an overview.
Antonio De Pascalis, Giuseppe Cianciolo, Irene Capelli, Giuliano Brunori, Gaetano La Manna. J Nephrol 2021
7

Does SGLT2 Inhibition Affect Sympathetic Nerve Activity in Type 2 Diabetes?
Rumyana Dimova, Tsvetalina Tankova. Horm Metab Res 2021
3


Medical management of resistant hypertension: the role of sodium-glucose cotransporter 2 inhibitors (SGLT2i).
Muhannad Alqudsi, Juan Carlos Q Velez, Jose Navarrete. Curr Opin Cardiol 2021
3

Current Challenges and Future Perspectives of Renal Tubular Dysfunction in Diabetic Kidney Disease.
Suyan Duan, Fang Lu, Dandan Song, Chengning Zhang, Bo Zhang, Changying Xing, Yanggang Yuan. Front Endocrinol (Lausanne) 2021
3

Reduction of estimated fluid volumes following initiation of empagliflozin in patients with type 2 diabetes and cardiovascular disease: a secondary analysis of the placebo-controlled, randomized EMBLEM trial.
Atsushi Tanaka, Michio Shimabukuro, Hiroki Teragawa, Yosuke Okada, Toshinari Takamura, Isao Taguchi, Shigeru Toyoda, Hirofumi Tomiyama, Shinichiro Ueda, Yukihito Higashi,[...]. Cardiovasc Diabetol 2021
5